Literature DB >> 16160163

Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections.

Ute-Christiane Meier1, Rachel E Owen, Elizabeth Taylor, Andrew Worth, Nikolai Naoumov, Christian Willberg, Kwok Tang, Phillipa Newton, Pierre Pellegrino, Ian Williams, Paul Klenerman, Persephone Borrow.   

Abstract

Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) cause clinically important persistent infections. The effects of virus persistence on innate immunity, including NK cell responses, and the underlying mechanisms are not fully understood. We examined the frequency, phenotype, and function of peripheral blood CD3- CD56+ NK subsets in HIV+ and HCV+ patients and identified significantly reduced numbers of total NK cells and a striking shift in NK subsets, with a marked decrease in the CD56(dim) cell fraction compared to CD56(bright) cells, in both infections. This shift influenced the phenotype and functional capacity (gamma interferon production, killing) of the total NK pool. In addition, abnormalities in the functional capacity of the CD56(dim) NK subset were observed in HIV+ patients. The shared NK alterations were found to be associated with a significant reduction in serum levels of the innate cytokine interleukin 15 (IL-15). In vitro stimulation with IL-15 rescued NK cells of HIV+ and HCV+ patients from apoptosis and enhanced proliferation and functional activity. We hypothesize that the reduced levels of IL-15 present in the serum during HIV and HCV infections might impact NK cell homeostasis, contributing to the common alterations of the NK pool observed in these unrelated infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160163      PMCID: PMC1211534          DOI: 10.1128/JVI.79.19.12365-12374.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.

Authors:  R P Bucy; R D Hockett; C A Derdeyn; M S Saag; K Squires; M Sillers; R T Mitsuyasu; J M Kilby
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

2.  Viral clearance without destruction of infected cells during acute HBV infection.

Authors:  L G Guidotti; R Rochford; J Chung; M Shapiro; R Purcell; F V Chisari
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

3.  Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection.

Authors:  J Corado; F Toro; H Rivera; N E Bianco; L Deibis; J B De Sanctis
Journal:  Clin Exp Immunol       Date:  1997-09       Impact factor: 4.330

4.  IL-15 enhances immune functions during HIV infection.

Authors:  J Chehimi; J D Marshall; O Salvucci; I Frank; S Chehimi; S Kawecki; D Bacheller; S Rifat; S Chouaib
Journal:  J Immunol       Date:  1997-06-15       Impact factor: 5.422

Review 5.  Natural killer cells in antiviral defense: function and regulation by innate cytokines.

Authors:  C A Biron; K B Nguyen; G C Pien; L P Cousens; T P Salazar-Mather
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

6.  Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15.

Authors:  X Zhang; S Sun; I Hwang; D F Tough; J Sprent
Journal:  Immunity       Date:  1998-05       Impact factor: 31.745

7.  Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15.

Authors:  H Yu; T A Fehniger; P Fuchshuber; K S Thiel; E Vivier; W E Carson; M A Caligiuri
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

Review 8.  Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems.

Authors:  N S Williams; J Klem; I J Puzanov; P V Sivakumar; J D Schatzle; M Bennett; V Kumar
Journal:  Immunol Rev       Date:  1998-10       Impact factor: 12.988

9.  Cytolytic activity against allogeneic human endothelia: resistance of cytomegalovirus-infected cells and virally activated lysis of uninfected cells.

Authors:  W J Waldman; D A Knight; P W Adams
Journal:  Transplantation       Date:  1998-07-15       Impact factor: 4.939

10.  Human herpesvirus-6 enhances natural killer cell cytotoxicity via IL-15.

Authors:  L Flamand; I Stefanescu; J Menezes
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808

View more
  80 in total

1.  CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections.

Authors:  Chelsey J Judge; Lenche Kostadinova; Kenneth E Sherman; Adeel A Butt; Yngve Falck-Ytter; Nicholas T Funderburg; Alan L Landay; Michael M Lederman; Scott F Sieg; Johan K Sandberg; Donald D Anthony
Journal:  J Leukoc Biol       Date:  2017-04-11       Impact factor: 4.962

2.  Longitudinal analysis of activation markers on monocyte subsets during the development of simian immunodeficiency virus encephalitis.

Authors:  Stephanie J Bissel; Guoji Wang; Anita M Trichel; Michael Murphey-Corb; Clayton A Wiley
Journal:  J Neuroimmunol       Date:  2006-06-21       Impact factor: 3.478

3.  High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer.

Authors:  Cheng Sun; Jing Xu; Qiang Huang; Mei Huang; Hao Wen; Chuanshan Zhang; Jinyu Wang; Jiaxi Song; Meijuan Zheng; Haoyu Sun; Haiming Wei; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

4.  The natural killer cell interferon-gamma response to bacteria is diminished in untreated HIV-1 infection and defects persist despite viral suppression.

Authors:  Stephanie M Dillon; Eric J Lee; Julia M Bramante; Edward Barker; Cara C Wilson
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

5.  Activation of natural killer cells during acute infection with hepatitis C virus.

Authors:  Barbara Amadei; Simona Urbani; Angelica Cazaly; Paola Fisicaro; Alessandro Zerbini; Parvin Ahmed; Gabriele Missale; Carlo Ferrari; Salim I Khakoo
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

Review 6.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

7.  A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action.

Authors:  A J MacDonald; N A Libri; S Lustigman; S J Barker; M A Whelan; A E Semper; W M Rosenberg
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

8.  IL-21 augments natural killer effector functions in chronically HIV-infected individuals.

Authors:  Natasa Strbo; Lesley de Armas; Huanliang Liu; Michael A Kolber; Mathias Lichtenheld; Savita Pahwa
Journal:  AIDS       Date:  2008-08-20       Impact factor: 4.177

Review 9.  A new insight into hepatitis C vaccine development.

Authors:  Chun I Yu; Bor-Luen Chiang
Journal:  J Biomed Biotechnol       Date:  2010-06-13

10.  Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines.

Authors:  Damien Sène; Franck Levasseur; Michal Abel; Marion Lambert; Xavier Camous; Céline Hernandez; Véronique Pène; Arielle R Rosenberg; Evelyne Jouvin-Marche; Patrice N Marche; Patrice Cacoub; Sophie Caillat-Zucman
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.